fda revives oxigene's thyroid cancer drug hopes, shares surge
oxigene inc said u.s. health regulators indicated that its experimental thyroid cancer drug may warrant further development, cheering investors a month after the company stopped enrollment in a drug trial.
http://feeds.reuters.com/~r/reuters/healthnews/~3/ssm1kutivkw/us-oxigene-idustre72k33320110321
8083
21 Mar 2011 17:55:40
reuters
health